Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The FDA announced the approval of Teva’s Capecitabine Tablets, the first generic version of Roche’s Xeloda.
Xeloda is a fluoropyrimidine indicated for first-line treatment of metastatic colorectal carcinoma when fluoropyrimidine therapy alone is preferred; and as adjuvant treatment of Dukes’ C colon cancer after complete resection of the primary tumor when fluoropyrimidine therapy alone is preferred.
RELATED: Oncology Resource Center
Xeloda is also indicated for metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel when further anthracycline therapy is not indicated; and with docetaxel for metastatic breast cancer after failure of prior anthracycline-containing regimen.
Teva has gained approval to market Capecitabine 150mg and 500mg strength tablets.
For more information call (888) TEVA-USA or visit TevaUSA.com.
